Skip to Content
Søg Menu
Velkommen til lungecancer

Få de seneste artikler og MEDtalks om lungecancer

Seneste nyt om lungecancer

Lung Cancer Insights: What’s New in the Field – January Update

  • / Jan Andreasen / Amanda Feldballe Bernholm

Danish and Nordic Lung Cancer Insights – January Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer
Matilde Grupe Frost

Gender-Based Outcomes in Advanced NSCLC

/ Matilde Grupe Frost
NSCLCLungecancer Play the Video
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungecancer Play the Video
Pasi Jänne

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

/ Pasi Jänne
WCLC25NSCLCLungecancer Play the Video

Lung Cancer Highlights

Danish and Nordic Lung Cancer Insights – December Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Danish and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Lung Cancer Insights: What’s New in the Field

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

MEDtalks

Michael Stenger

WCLC 2025: Lung Cancer Screening and Early Results from the Danish PLUS Trial

/ Michael Stenger
WCLC25Lungecancer Play the Video
Maria Silvoniemi

Clinical Dilemmas in the Management of NSCLC Without Driver Mutations

/ Maria Silvoniemi
NSCLCLungecancer Play the Video
Edyta Maria Urbanska

Behandling af patienter med lungecancer og positiv for NTRK-fusioner

/ Edyta Maria Urbanska
Lungecancer Play the Video
Luis Paz-Ares

ASCO 2025: Lurbinectedin–Atezolizumab Improves Survival in SCLC

/ Luis Paz-Ares
ASCO25Lungecancer Play the Video
Odd Terje Brustugun

Perspektiver på behandlingsvalg ved NSCLC uten drivermutasjoner

/ Odd Terje Brustugun
Lungecancer Play the Video
Edyta Maria Urbanska

Amivantamab + lazartinib i 1.-linje øger overlevelsen ved avanceret EGFR muteret NSCLC vs osimertinib

/ Edyta Maria Urbanska
Lungecancer Play the Video
Hent flere

Artikler

Behandling af ALK-positiv NSCLC med lorlatinib i 1. linje giver markante kliniske fordele 

/ Jon Alexander Lykkegaard Andersen / Jan Andreasen
NSCLCLungecancer

Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%

/ Jan Andreasen
LungecancerImmunterapi

Lung Cancer Insights: What’s New in the Field – December Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Danish and Nordic Lung Cancer Insights – December Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Danish and Nordic Lung Cancer Insights – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer

Lung Cancer Insights: What’s New in the Field – October Update

/ Jan Andreasen / Amanda Feldballe Bernholm
lung cancer-highlightsLungecancer
Back to top